[Resection margins in soft tissue sarcomas].
Resektionsgrenzen bei Weichteilsarkomen.
Extremities
Fascia
Local neoplasm recurrences
Prognostic factors
Tumor grading
Journal
Der Orthopade
ISSN: 1433-0431
Titre abrégé: Orthopade
Pays: Germany
ID NLM: 0331266
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
pubmed:
30
8
2019
medline:
27
9
2019
entrez:
30
8
2019
Statut:
ppublish
Résumé
Soft tissue sarcomas (STS) are a rare and heterogeneous group of malignant tumors that arise from the mesenchymal tissue. STS can form anywhere in the human body, with the extremities being preferred sites of predilection. A fundamental pillar of treatment is the surgical resection of soft tissue sarcomas. The goal is always an R0 resection with a safety margin. There is no consensus in the literature about the desired tumor-free resection margin. The decisive factors for these resection margins are histopathology, presence of anatomical barriers (capsule, tendon, fascia, cartilage, periosteum) and possibilities of (neo-) adjuvant therapy. References in the literature support the role of resection margins as a predictor of local recurrence. Regarding the role of resection margins in overall survival, available data is divergent. There are known prognostic factors that influence overall survival, such as histological subtype, tumor size, tumor grading, and presence of metastases. So far, several studies have attempted to quantify the margins of resection, but no consensus has been reached, and debates are ongoing. When analyzing all the results of the data in the literature, it seems appropriate to aim for a negative resection margin >1 mm including an anatomical border structure, if possible.
Sections du résumé
BACKGROUND
BACKGROUND
Soft tissue sarcomas (STS) are a rare and heterogeneous group of malignant tumors that arise from the mesenchymal tissue. STS can form anywhere in the human body, with the extremities being preferred sites of predilection.
TREATMENT
METHODS
A fundamental pillar of treatment is the surgical resection of soft tissue sarcomas. The goal is always an R0 resection with a safety margin. There is no consensus in the literature about the desired tumor-free resection margin. The decisive factors for these resection margins are histopathology, presence of anatomical barriers (capsule, tendon, fascia, cartilage, periosteum) and possibilities of (neo-) adjuvant therapy.
DISCUSSION
CONCLUSIONS
References in the literature support the role of resection margins as a predictor of local recurrence. Regarding the role of resection margins in overall survival, available data is divergent. There are known prognostic factors that influence overall survival, such as histological subtype, tumor size, tumor grading, and presence of metastases. So far, several studies have attempted to quantify the margins of resection, but no consensus has been reached, and debates are ongoing. When analyzing all the results of the data in the literature, it seems appropriate to aim for a negative resection margin >1 mm including an anatomical border structure, if possible.
Identifiants
pubmed: 31463543
doi: 10.1007/s00132-019-03795-6
pii: 10.1007/s00132-019-03795-6
doi:
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
768-775Références
Eur J Cancer. 2000 Apr;36(6):710-6
pubmed: 10762742
Ann Surg. 2002 Mar;235(3):424-34
pubmed: 11882765
Ann Surg. 2003 Feb;237(2):218-26
pubmed: 12560780
Lancet Oncol. 2003 Jun;4(6):335-42
pubmed: 12788405
J Surg Oncol. 2004 Feb;85(2):68-76
pubmed: 14755506
Clin Orthop Relat Res. 2004 Feb;(419):165-72
pubmed: 15021149
J Clin Oncol. 2005 Jan 1;23(1):96-104
pubmed: 15625364
Proc (Bayl Univ Med Cent). 2003 Jul;16(3):285-90
pubmed: 16278699
ANZ J Surg. 2006 Mar;76(3):104-9
pubmed: 16626341
Ann Surg Oncol. 2007 May;14(5):1583-90
pubmed: 17260106
Br J Surg. 2008 Feb;95(2):237-43
pubmed: 17703500
Cancer. 2009 Aug 1;115(15):3483-8
pubmed: 19536900
Ann Oncol. 2010 May;21(5):1106-11
pubmed: 19858086
Sarcoma. 2010;2010:506182
pubmed: 20634933
Clin Orthop Relat Res. 2010 Nov;468(11):3003-11
pubmed: 20645035
Ann Surg Oncol. 2011 Mar;18(3):720-5
pubmed: 20878245
J Surg Oncol. 2010 Nov 1;102(6):626-33
pubmed: 20886550
Cancer. 2012 Jun 15;118(12):3199-207
pubmed: 22020375
Clin Orthop Relat Res. 2012 Mar;470(3):692-9
pubmed: 22090354
Cancer. 2012 Nov 1;118(21):5339-48
pubmed: 22517534
Clin Transl Oncol. 2012 Jul;14(7):541-4
pubmed: 22721800
Sarcoma. 2012;2012:290698
pubmed: 22761544
Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9
pubmed: 22997462
Curr Oncol. 2013 Jun;20(3):e247-54
pubmed: 23737694
J Orthop Sci. 2014 Jan;19(1):141-9
pubmed: 24081391
J Bone Joint Surg Am. 2013 Oct 16;95(20):e151
pubmed: 24132366
Histopathology. 2014 Jan;64(1):2-11
pubmed: 24164390
Cancer. 2014 Sep 15;120(18):2866-75
pubmed: 24894656
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Ann Plast Surg. 2016 Mar;76 Suppl 1:S8-12
pubmed: 26808737
Oncologist. 2016 Oct;21(10):1269-1276
pubmed: 27440063
Ann Surg Oncol. 2017 Jun;24(6):1596-1605
pubmed: 28108827
World J Surg. 2017 Jun;41(6):1534-1541
pubmed: 28116485
Oncologist. 2017 Nov;22(11):1400-1410
pubmed: 28739867
J Clin Oncol. 2018 Mar 1;36(7):704-709
pubmed: 29346043
J Orthop Sci. 2018 May;23(3):441-448
pubmed: 29459081
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
Eur J Cancer. 2019 Mar;109:51-60
pubmed: 30690293
Sarcoma. 2019 Mar 5;2019:1342615
pubmed: 30956533
Chirurg. 2019 Jun;90(6):457-461
pubmed: 31053897
J Surg Oncol. 2019 Sep;120(3):325-331
pubmed: 31172531
Surg Oncol. 2019 Jun;29:84-89
pubmed: 31196499
Cancer. 1981 Mar 1;47(5):1005-22
pubmed: 7226034
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
Cancer. 1996 Nov 15;78(10):2247-57
pubmed: 8918421